Summary

The global IVD reagents market is valued at an estimated 87.41 billion in 2029 and is projected to reach USD 60.45 billion by 2024, at a CAGR of 7.7% during the forecast period. The increasing adoption of IVD technologies has led to a growing need of IVD reagents. The demand for IVD reagents is therefore expected to increase as new diagnostic technologies are getting FDA, EMA approvals from regulatory bodies.
“The oligonucleotide segment is projected to witness the highest growth rate in the IVD reagents market, by type, during the forecast period.”
Based on type, the IVD reagents market is segmented into antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents. The growing adoption of PCR-based tests in diagnostics has boosted the demand for oligonucleotide in the IVD reagents market. Oligonucleotides have wide range of applications in infectious diseases and genetic testing.
“The infectious disease segment to witness the highest share in the IVD reagents market, in 2023, by application”
Based on application, the IVD reagents market is segmented into infectious diseases, oncological applications, endocrinological applications, cardiological applications, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing and other applications. The infectious diseases segment experience highest market share of IVD reagents market due to rising number of R&D activities and product approvals for infectious disease applications.
“The Asia Pacific region is projected to witness highest growth rate in the IVD reagents market during the forecast period”
The global IVD reagents market is segmented into six regions - North America, Europe, Asia Pacific, the Middle East & Africa, Latin America, and the GCC Countries. Over the span of the forecast period, the IVD reagents market is expected to grow at the fastest rate in the Asia Pacific region. Over the projected period, the Asia Pacific market is expected to develop at the greatest rate due to factors such increasing healthcare spending and an extensive population base.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 42%, Tier 2 - 30%, and Tier 3 - 28%
• By Designation: C-level - 46%, Director-level - 23%, and Others - 31%
• By Region: North America – 23%, Europe – 44%, Asia Pacific – 28%, Latin America – 3%, Middle East & Africa – 1%, and the GCC Countries – 1%
Lists of Companies Profiled in the Report:
Danaher Corporation (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), BioMerieux (France), BD (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), DiaSorin S.p.A (Italy), Grifols, S.A. (Spain), Werfen, S.A. (Spain), QuidelOrtho Corporation (US), Chembio Diagnostics, Inc. (US), Surmodics, Inc. (US), Merck KGaA (Germany), MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. (Tokyo), Canvax (Spain), Prestige Diagnostics (US), Adaltis S.r.l. (Italy), and Randox Laboratories Ltd. (UK)
Study Coverage:
In this report, the IVD reagents market has been categorized based on type (antibodies, antigen, purified proteins, and peptides, oligonucleotides, nucleic acid probes, and other IVD reagents), technology (immunoassays, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, chromatography & mass spectrometry, immunohistochemistry), application (infectious diseases, oncological applications, endocrinological application, cardiology application, blood screening, genetic testing, autoimmune diseases, allergy diagnostics, drug monitoring & testing, and other applications), test type (laboratory test, and point-of-care tests), end user (hospitals & clinics, clinical laboratories, blood banks, home care settings, pharmaceutical & biotechnology companies, academic institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries).
Information regarding the main drivers, restraints, opportunities, and challenges influencing the IVD reagents market's expansion is includes detail in this study. An intensive study of the key players in the IVD reagents market has been done to provide insights into their business profile, service offered, note worthy strategies, acquisitions and expansions, and other deals made pertaining to the market. This study examines the fragmented landscape of emerging IVD reagents startups.
Reasons to buy this report:
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall IVD reagents marketand the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, challenges, opportunities, and restaints.
The report provides insights on the following pointers:
• Analysis of key drivers: (growing geriatric population, gradual shift towards point-of-care testing and automated analyzers, rise in early diagnosis and personalized medicine, increasing adoption of third-party quality controls, growing biotechnology and biopharmaceutical industries, increasing funding for R&D activities), restraints (unfavorable reimbursement scenario, stringent regulatory requirements), opportunities (increasing development of biomarkers, rising significance of companion diagnostics, market growth opportunities in emerging economies, and growing trend of digitalization), and challenges (operational challenges in clinical process) influencing the growth of the in IVD reagents market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the IVD reagents market across varied regions.
• Market Diversification: Exhaustive information about untapped geographies, and investments in the IVD reagents market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like include F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Danaher Corporation (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific Inc. (US) are among others, in the IVD reagents market strategies.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKETS COVERED AND REGIONAL SCOPE 39
1.3.2 INCLUSIONS AND EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 41
1.4 CURRENCY CONSIDERED 41
1.5 STAKEHOLDERS 41
1.6 MARKET RECONCILIATION 41
2 RESEARCH METHODOLOGY 42
2.1 RESEARCH DATA 42
2.1.1 SECONDARY DATA 43
2.1.1.1 Key data from secondary sources 44
2.1.2 PRIMARY DATA 44
2.1.2.1 Primary sources 45
2.1.2.2 Key industry insights 46
2.1.2.3 Key data from primary sources 46
2.1.2.4 Breakdown of primary interviews 47
2.2 MARKET SIZE ESTIMATION 48
2.2.1 BOTTOM-UP APPROACH 48
2.2.1.1 Approach 1: Company revenue estimation approach 48
2.2.1.2 Approach 2: Presentations of companies and primary interviews 49
2.2.1.3 Approach 3: Primary interviews 49
2.2.1.4 Growth forecast 49
2.2.1.5 CAGR projections 49
2.2.2 TOP-DOWN APPROACH 50
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 51
2.4 RESEARCH ASSUMPTIONS 52
2.4.1 STUDY-RELATED ASSUMPTIONS 52
2.4.2 PARAMETRIC ASSUMPTIONS 52
2.5 RESEARCH LIMITATIONS 53
2.6 RISK ASSESSMENT 53
3 EXECUTIVE SUMMARY 54

4 PREMIUM INSIGHTS 59
4.1 IVD REAGENTS MARKET OVERVIEW 59
4.2 ASIA PACIFIC: IVD REAGENTS MARKET, BY COUNTRY 60
4.3 NORTH AMERICA: IVD REAGENTS MARKET, BY TEST TYPE AND COUNTRY 60
4.4 IVD REAGENTS MARKET, BY COUNTRY 61
5 MARKET OVERVIEW 62
5.1 INTRODUCTION 62
5.2 MARKET DYNAMICS 62
5.2.1 DRIVERS 63
5.2.1.1 Growing geriatric population 63
5.2.1.2 Gradual shift toward point-of-care testing and automated analyzers 64
5.2.1.3 Rise in early diagnosis and personalized medicine 65
5.2.1.4 Increasing adoption of third-party quality controls 66
5.2.1.5 Growing biotechnology and biopharmaceutical industries 67
5.2.1.6 Increasing funding for R&D activities 67
5.2.2 RESTRAINTS 68
5.2.2.1 Unfavorable reimbursement scenario 68
5.2.2.2 Stringent regulatory requirements 68
5.2.3 OPPORTUNITIES 69
5.2.3.1 Increasing development of biomarkers 69
5.2.3.2 Rising significance of companion diagnostics 70
5.2.3.3 Market growth opportunities in emerging economies 71
5.2.3.4 Growing trend of digitalization 72
5.2.4 CHALLENGES 73
5.2.4.1 Operational challenges in clinical process 73
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 74
5.4 PRICING ANALYSIS 75
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION 75
5.4.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY REGION 76
5.4.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY 77
5.5 VALUE CHAIN ANALYSIS 77
5.6 SUPPLY CHAIN ANALYSIS 79
5.7 ECOSYSTEM ANALYSIS 80
5.8 INVESTMENT AND FUNDING SCENARIO 81
5.9 TECHNOLOGY ANALYSIS 81
5.9.1 KEY TECHNOLOGIES 82
5.9.2 ADJACENT TECHNOLOGIES 83
5.9.2.1 Multiplexed point-of-care testing 83
5.9.2.2 Nucleic acid lateral flow immunoassay 83
5.9.2.3 DNA-based detection 83
5.9.2.4 Immunodiagnostics 83
5.9.2.5 Dual path technology 83
5.10 PATENT ANALYSIS 84
5.11 TRADE ANALYSIS 85
5.11.1 IMPORT DATA 85
5.11.2 EXPORT DATA 85
5.12 KEY CONFERENCES AND EVENTS, 2024−2025 86
5.13 PORTER’S FIVE FORCES ANALYSIS 86
5.13.1 THREAT OF NEW ENTRANTS 87
5.13.2 THREAT OF SUBSTITUTES 87
5.13.3 BARGAINING POWER OF SUPPLIERS 88
5.13.4 BARGAINING POWER OF BUYERS 88
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 88
5.14 REGULATORY ANALYSIS 88
5.14.1 REGULATORY LANDSCAPE 88
5.14.1.1 North America 89
5.14.1.1.1 US 89
5.14.1.1.2 Canada 90
5.14.1.2 Europe 90
5.14.1.3 Asia Pacific 92
5.14.1.3.1 China 92
5.14.1.3.2 Japan 92
5.14.1.3.3 India 93
5.14.1.4 Latin America 93
5.14.1.4.1 Brazil 93
5.14.1.5 Middle East 94
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.14.2.1 North America 94
5.14.2.2 Europe 95
5.14.2.3 Asia Pacific 95
5.14.2.4 Latin America 96
5.14.2.5 Middle East & Africa 96
5.14.2.6 GCC Countries 96
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 97
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
5.15.2 BUYING CRITERIA 98
5.16 IMPACT OF AI/GENERATIVE AI ON IVD REAGENTS MARKET 98
5.16.1 INTRODUCTION 98
5.16.2 MARKET POTENTIAL FOR IVD REAGENTS 98
5.16.3 AI USE CASES 99
5.16.4 KEY COMPANIES IMPLEMENTING AI 100
5.16.5 FUTURE OF GENERATIVE AI ON IVD REAGENTS 100
6 IVD REAGENTS MARKET, BY TYPE 101
6.1 INTRODUCTION 102
6.2 ANTIBODIES 102
6.2.1 MONOCLONAL ANTIBODIES 105
6.2.1.1 Increasing incidence of cancer to stimulate growth 105
6.2.2 POLYCLONAL ANTIBODIES 107
6.2.2.1 Rising prevalence of infectious diseases and autoimmune disorders
to support growth 107
6.3 ANTIGENS, PURIFIED PROTEINS, AND PEPTIDES 110
6.3.1 INCREASING FOCUS ON ADVANCED PRECISION MEDICINE
TO ENCOURAGE GROWTH 110
6.4 OLIGONUCLEOTIDES 113
6.4.1 GROWING INCLINATION TOWARD MOLECULAR DIAGNOSTICS TO DRIVE MARKET 113
6.5 NUCLEIC ACID PROBES 116
6.5.1 NEED FOR EARLY DISEASE DETECTION AND MONITORING LOW-ABUNDANCE BIOMARKERS TO AID GROWTH 116
6.6 OTHER IVD REAGENTS 119
7 IVD REAGENTS MARKET, BY TECHNOLOGY 123
7.1 INTRODUCTION 124
7.2 IMMUNOASSAYS 124
7.2.1 RISING TREND OF AUTOMATION TO PROMOTE GROWTH 124
7.3 CLINICAL CHEMISTRY 128
7.3.1 RISING PREVALENCE OF DIABETES TO BOOST SEGMENT 128
7.4 MOLECULAR DIAGNOSTICS 131
7.4.1 GROWING DEMAND FOR BLOOD SCREENING AND POINT-OF-CARE TESTING
TO FUEL MARKET 131
7.5 HEMATOLOGY 133
7.5.1 INCREASING FOCUS ON STEM CELL RESEARCH TO SPEED UP GROWTH 133
7.6 MICROBIOLOGY 136
7.6.1 RISING PREVALENCE OF MICROBIAL INFECTIONS TO FUEL MARKET 136
7.7 COAGULATION & HEMOSTASIS 138
7.7.1 GROWING USE OF ANTICOAGULATION THERAPY TO PROPEL MARKET 138
7.8 URINALYSIS 141
7.8.1 RISING PREVALENCE OF KIDNEY DISEASES TO SUPPORT MARKET GROWTH 141
7.9 CHROMATOGRAPHY & MASS SPECTROMETRY 144
7.9.1 INCREASING APPLICATIONS IN DISEASE SCREENING, FORENSIC ANALYSIS,
AND DRUG THERAPY TO BOOST MARKET 144
7.10 IMMUNOHISTOCHEMISTRY 146
7.10.1 GROWING NUMBER OF LABORATORY TESTS FOR CANCER DIAGNOSIS
TO DRIVE MARKET 146

8 IVD REAGENTS MARKET, BY APPLICATION 150
8.1 INTRODUCTION 151
8.2 INFECTIOUS DISEASES 151
8.2.1 INCREASING PRODUCT LAUNCHES AND APPROVALS TO BOOST MARKET 151
8.3 ONCOLOGICAL APPLICATIONS 154
8.3.1 GROWING EMPHASIS ON EARLY DIAGNOSIS AND QUALITY TREATMENT
TO FUEL MARKET 154
8.4 ENDOCRINOLOGICAL APPLICATIONS 157
8.4.1 RISING PREVALENCE OF DIABETES AND THYROID-RELATED DISORDERS
TO SUSTAIN GROWTH 157
8.5 CARDIOLOGICAL APPLICATIONS 160
8.5.1 CHANGING LIFESTYLES IN DEVELOPED AND DEVELOPING COUNTRIES
TO PROPEL MARKET 160
8.6 BLOOD SCREENING 163
8.6.1 RISING ADOPTION OF AUTOMATED DIAGNOSTIC INSTRUMENTS
TO FACILITATE GROWTH 163
8.7 GENETIC TESTING 166
8.7.1 INCREASING ADOPTION OF GENETIC TESTING TO DIAGNOSE RARE
AND FATAL DISEASES TO SUSTAIN GROWTH 166
8.8 AUTOIMMUNE DISEASES 169
8.8.1 GROWING ADVANCEMENTS IN LABORATORY TECHNOLOGY, REAGENTS,
AND ALTERNATIVE ASSAY METHODOLOGIES TO DRIVE MARKET 169
8.9 ALLERGY DIAGNOSTICS 172
8.9.1 GROWING FOCUS ON ALLERGY THERAPY AND PREVENTION
TO ACCELERATE GROWTH 172
8.10 DRUG MONITORING & TESTING 175
8.10.1 GROWING IMPLEMENTATION OF DRUGS-OF-ABUSE TESTING TO DRIVE MARKET 175
8.11 OTHER APPLICATIONS 178
9 IVD REAGENTS MARKET, BY TEST TYPE 182
9.1 INTRODUCTION 183
9.2 LABORATORY TESTS 183
9.2.1 INCREASING NEED FOR AUTOMATION TO EXPEDITE GROWTH 183
9.3 POINT-OF-CARE TESTS 186
9.3.1 NEED TO CLOSELY MONITOR PATIENT CONDITIONS TO AUGMENT GROWTH 186
10 IVD REAGENTS MARKET, BY END USER 190
10.1 INTRODUCTION 191
10.2 HOSPITALS & CLINICS 191
10.2.1 INCREASING SPECIALTY DIAGNOSTIC TESTS TO ACCELERATE GROWTH 191
10.3 CLINICAL LABORATORIES 194
10.3.1 LARGE REFERENCE LABORATORIES 198
10.3.1.1 Need for specialized testing capabilities and minimal turnaround
time to boost market 198
10.3.2 SMALL & MEDIUM-SIZED LABORATORIES 201
10.3.2.1 Growing adoption of automated and semi-automated instruments
to support growth 201
10.4 BLOOD BANKS 203
10.4.1 GROWING NUMBER OF TRAUMA CASES AND AVAILABILITY OF SOPHISTICATED SURGICAL PROCEDURES TO FUEL MARKET 203
10.5 HOME CARE SETTINGS 206
10.5.1 GROWING PREFERENCE FOR AT-HOME TESTING KITS TO DRIVE MARKET 206
10.6 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 209
10.6.1 INCREASING RESEARCH & DEVELOPMENT EFFORTS TO CONTRIBUTE
TO GROWTH 209
10.7 ACADEMIC INSTITUTES 212
10.7.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS TO FAVOR GROWTH 212
10.8 OTHER END USERS 216
11 IVD REAGENTS MARKET, BY REGION 219
11.1 INTRODUCTION 220
11.2 NORTH AMERICA 220
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 221
11.2.2 US 226
11.2.2.1 Established reimbursement framework to drive market 226
11.2.3 CANADA 230
11.2.3.1 Rising incidence of chronic and infectious lifestyle diseases
to propel market 230
11.3 EUROPE 235
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 236
11.3.2 GERMANY 240
11.3.2.1 Increasing investments in clinical diagnostics research to drive market 240
11.3.3 UK 244
11.3.3.1 Rising adoption of genome-based testing to promote growth 244
11.3.4 FRANCE 248
11.3.4.1 High healthcare expenditure and rising investments in genomic
medicine to boost market 248
11.3.5 ITALY 251
11.3.5.1 Growing geriatric population and subsequent rise in chronic
conditions to support market growth 251
11.3.6 SPAIN 255
11.3.6.1 Rising adoption of immunoassay reagents to drive market 255
11.3.7 REST OF EUROPE 258
11.4 ASIA PACIFIC 263
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 263
11.4.2 JAPAN 268
11.4.2.1 Rise in social health insurance programs to encourage growth 268

11.4.3 CHINA 272
11.4.3.1 Growing focus on preventive care to boost demand 272
11.4.4 INDIA 276
11.4.4.1 Rising prevalence of chronic diseases to fuel market 276
11.4.5 REST OF ASIA PACIFIC 280
11.5 LATIN AMERICA 284
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 284
11.5.2 BRAZIL 288
11.5.2.1 Rising prevalence of diabetes to stimulate growth 288
11.5.3 MEXICO 291
11.5.3.1 Growing establishment of clinical laboratories to boost market 291
11.5.4 REST OF LATIN AMERICA 295
11.6 MIDDLE EAST & AFRICA 298
11.6.1 GROWING FOCUS ON IMMUNOLOGY AND PRENATAL & CANCER TESTING
TO DRIVE MARKET 298
11.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 299
11.7 GCC COUNTRIES 303
11.7.1 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 303
11.7.2 KINGDOM OF SAUDI ARABIA 307
11.7.2.1 Rising healthcare expenditure to promote growth 307
11.7.3 UNITED ARAB EMIRATES 310
11.7.3.1 Increasing development of advanced healthcare infrastructure
to expedite growth 310
11.7.4 OTHER GCC COUNTRIES 314
12 COMPETITIVE LANDSCAPE 318
12.1 OVERVIEW 318
12.2 KEY PLAYER STRATEGY/RIGHT TO WIN, 2023 318
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IVD REAGENTS
MARKET, 2021–2023 318
12.3 REVENUE ANALYSIS, 2021−2023 319
12.4 MARKET SHARE ANALYSIS, 2023 320
12.5 COMPANY VALUATION AND FINANCIAL METRICS 322
12.6 BRAND/PRODUCT COMPARISON 324
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 325
12.7.1 STARS 325
12.7.2 EMERGING LEADERS 325
12.7.3 PERVASIVE PLAYERS 325
12.7.4 PARTICIPANTS 325
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 327
12.7.5.1 Company footprint 327
12.7.5.2 Technology footprint 328

12.7.5.3 Application footprint 329
12.7.5.4 Test type footprint 330
12.7.5.5 Region footprint 331
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 332
12.8.1 PROGRESSIVE COMPANIES 332
12.8.2 RESPONSIVE COMPANIES 332
12.8.3 DYNAMIC COMPANIES 332
12.8.4 STARTING BLOCKS 332
12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 334
12.8.5.1 Detailed list of key startups/SMEs 334
12.8.5.2 Competitive benchmarking of key startups/SMEs 334
12.9 COMPETITIVE SCENARIO 335
12.9.1 PRODUCT LAUNCHES AND APPROVALS 335
12.9.2 DEALS 336
12.9.3 EXPANSIONS 337
12.9.4 OTHER DEVELOPMENTS 337
13 COMPANY PROFILES 338
13.1 KEY PLAYERS 338
13.1.1 DANAHER CORPORATION 338
13.1.1.1 Business overview 338
13.1.1.2 Products offered 339
13.1.1.3 Recent developments 340
13.1.1.3.1 Deals 340
13.1.1.3.2 Expansions 340
13.1.1.3.3 Other developments 340
13.1.1.4 MnM view 341
13.1.1.4.1 Right to win 341
13.1.1.4.2 Strategic choices 341
13.1.1.4.3 Weaknesses and competitive threats 341
13.1.2 F. HOFFMANN-LA ROCHE LTD. 342
13.1.2.1 Business overview 342
13.1.2.2 Products offered 343
13.1.2.3 Recent developments 344
13.1.2.3.1 Deals 344
13.1.2.4 MnM view 345
13.1.2.4.1 Right to win 345
13.1.2.4.2 Strategic choices 345
13.1.2.4.3 Weaknesses and competitive threats 345

13.1.3 ABBOTT 346
13.1.3.1 Business overview 346
13.1.3.2 Products offered 347
13.1.3.3 Recent developments 348
13.1.3.3.1 Deals 348
13.1.3.4 MnM view 349
13.1.3.4.1 Right to win 349
13.1.3.4.2 Strategic choices 349
13.1.3.4.3 Weaknesses and competitive threats 349
13.1.4 SIEMENS HEALTHINEERS AG 350
13.1.4.1 Business overview 350
13.1.4.2 Products offered 351
13.1.4.3 Recent developments 352
13.1.4.3.1 Deals 352
13.1.4.4 MnM view 353
13.1.4.4.1 Right to win 353
13.1.4.4.2 Strategic choices 353
13.1.4.4.3 Weaknesses and competitive threats 353
13.1.5 THERMO FISHER SCIENTIFIC INC. 354
13.1.5.1 Business overview 354
13.1.5.2 Products offered 355
13.1.5.3 Recent developments 356
13.1.5.3.1 Deals 356
13.1.5.3.2 Expansions 357
13.1.5.4 MnM view 358
13.1.5.4.1 Right to win 358
13.1.5.4.2 Strategic choices 358
13.1.5.4.3 Weaknesses and competitive threats 358
13.1.6 ILLUMINA, INC. 359
13.1.6.1 Business overview 359
13.1.6.2 Products offered 360
13.1.6.3 Recent developments 361
13.1.6.3.1 Deals 361
13.1.7 BIOMÉRIEUX 362
13.1.7.1 Business overview 362
13.1.7.2 Products offered 363
13.1.7.3 Recent developments 364
13.1.7.3.1 Deals 364
13.1.8 BD 365
13.1.8.1 Business overview 365
13.1.8.2 Products offered 367

13.1.8.3 Recent developments 367
13.1.8.3.1 Deals 367
13.1.9 HOLOGIC, INC. 368
13.1.9.1 Business overview 368
13.1.9.2 Products offered 370
13.1.9.3 Recent developments 371
13.1.9.3.1 Product launches and approvals 371
13.1.9.3.2 Deals 371
13.1.10 BIO-RAD LABORATORIES, INC. 372
13.1.10.1 Business overview 372
13.1.10.2 Products offered 374
13.1.10.3 Recent developments 374
13.1.10.3.1 Deals 374
13.1.11 SYSMEX CORPORATION 375
13.1.11.1 Business overview 375
13.1.11.2 Products offered 376
13.1.11.3 Recent developments 377
13.1.11.3.1 Product launches and approvals 377
13.1.11.3.2 Deals 377
13.1.11.3.3 Expansions 377
13.1.12 QIAGEN N.V. 378
13.1.12.1 Business overview 378
13.1.12.2 Products offered 379
13.1.12.3 Recent developments 380
13.1.12.3.1 Deals 380
13.1.13 AGILENT TECHNOLOGIES, INC. 381
13.1.13.1 Business overview 381
13.1.13.2 Products offered 383
13.1.13.3 Recent developments 384
13.1.13.3.1 Deals 384
13.1.13.3.2 Expansions 384
13.1.14 REVVITY 385
13.1.14.1 Business overview 385
13.1.14.2 Products offered 386
13.1.14.3 Recent developments 387
13.1.14.3.1 Deals 387
13.1.14.3.2 Other developments 387
13.1.15 DIASORIN S.P.A. 388
13.1.15.1 Business overview 388
13.1.15.2 Products offered 389
13.1.15.3 Recent developments 391
13.1.15.3.1 Deals 391
13.1.16 GRIFOLS, S.A. 392
13.1.16.1 Business overview 392
13.1.16.2 Products offered 393
13.1.16.3 Recent developments 394
13.1.16.3.1 Deals 394
13.1.17 WERFEN, S.A. 395
13.1.17.1 Business overview 395
13.1.17.2 Products offered 396
13.1.17.3 Recent developments 397
13.1.17.3.1 Deals 397
13.1.18 QUIDELORTHO CORPORATION 398
13.1.18.1 Business overview 398
13.1.18.2 Products offered 400
13.1.18.3 Recent developments 401
13.1.18.3.1 Deals 401
13.1.18.3.2 Expansions 401
13.1.19 CHEMBIO DIAGNOSTICS, INC. 402
13.1.19.1 Business overview 402
13.1.19.2 Products offered 403
13.1.20 SURMODICS, INC. 404
13.1.20.1 Business overview 404
13.1.20.2 Products offered 406
13.1.21 MERCK KGAA 407
13.1.21.1 Business overview 407
13.1.21.2 Products offered 408
13.2 OTHER PLAYERS 410
13.2.1 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. 410
13.2.2 CANVAX 411
13.2.3 PRESTIGE DIAGNOSTICS 412
13.2.4 ADALTIS S.R.L. 413
13.2.5 RANDOX LABORATORIES LTD. 414
14 APPENDIX 415
14.1 DISCUSSION GUIDE 415
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 420
14.3 CUSTOMIZATION OPTIONS 422
14.4 RELATED REPORTS 422
14.5 AUTHOR DETAILS 423